Table 2 COVID-19 patient characteristics
|  | Negative VTE (n = 22) | Positive for VTE (n = 9) | p-Value |
|---|---|---|---|
Demographics | |||
 Age (years), mean (SD) | 59.0 (17.2) | 59.5 (14.5) | – |
 Female, n (%) | 7 (31.8%) | 3 (33.3%) | – |
 BMI (kg/m2), mean (SD) | 31.3 (9.1) | 32.7 (9.1) | – |
 Prior anticoagulation therapy | 0 (0.0%) | 0 (0.0%) | – |
Comorbidities, n (%) | |||
 Hypertension | 11 (50.0%) | 2 (22.2%) | 0.15 |
 Cardiovascular disease | 0 (0.00%) | 4 (44.4%) | 0.0008 |
 COPD | 2 (9.09%) | 3 (33.3%) | 0.10 |
 OSA | 1 (4.55%) | 1 (11.1%) | 0.50 |
 Hepatitis | 0 (0.00%) | 1 (11.1%) | 0.11 |
 Peripheral vascular disease | 1 (4.55%) | 1 (11.1%) | 0.50 |
 Malignancy | 1 (4.55%) | 1 (11.1%) | 0.50 |
 Diabetes | 9 (40.9%) | 1 (11.1%) | 0.10 |
 Renal failure | 1 (4.55%) | 4 (44.4%) | 0.006 |
 Paraplegia | 0 (0.00%) | 1 (11.1%) | 0.11 |
 Singulitis | 0 (0.00%) | 1 (11.1%) | 0.11 |
Disposition, n (%) | |||
 ICU | 0 (0.00%) | 5 (55.5%) | 0.0001 |
 Intubation | 0 (0.00%) | 5 (55.5%) | 0.0001 |
 Death no. | 0 (0.00%) | 1 (11.1%) | 0.11 |